Agnucaston is typically used for symptoms related to the menstrual cycle.

---

What Agnucaston Treats: Main Uses and Benefits

Agnucaston's therapeutic domain includes relief from symptoms associated with Premenstrual Syndrome (PMS). This is a key indication for the medicine.

The common clinical scenarios of use involve addressing the collection of physical and emotional symptoms that may arise premenstrually. The therapeutic application is intended for the relief of premenstrual syndrome symptoms, which may include irritability, headache, breast fullness or tenderness (cyclic mastalgia), and bloating. The medicine focuses on providing relief from these minor complaints occurring premenstrually, specifically for women experiencing cyclical distress prior to their period.

---

Quick Facts

• Symptom addressed is: Cyclical Breast Tenderness
• Primary focus: Relief from symptoms of Premenstrual Syndrome (PMS)

Who Can and Cannot Use Agnucaston?

Eligibility Scope	Status Defined by Regulators
Allowed Population	Female adults (18 years and over).
Use Not Recommended	Children and adolescents under 18 years of age.
Contraindicated	Pregnancy, Lactation, Hypersensitivity, Current Pituitary Disorder.

Agnucaston's eligibility is strictly defined by regulatory authorities and is limited exclusively to adult women. Use is not recommended in children and adolescents under 18 because the product's safety and efficacy have not been established in these age groups.

The medicine is contraindicated if a patient is pregnant, breastfeeding, or has a known allergy to the chasteberry extract or its excipients. Use is also prohibited for individuals diagnosed with a current pituitary disorder due to the extract's effects on the hypothalamic-pituitary axis.

Specific restrictions apply to patients with a history of oestrogen-sensitive cancers or prolactin-secreting tumours of the pituitary gland. The official label requires special consideration for these populations, as the drug’s action may interfere with hormone-related conditions or mask critical symptoms. For individuals with hepatic or renal impairment, regulatory documents note that data regarding appropriate dosage are insufficient.

Interactions with other medicines and products

The official regulatory profile for Agnucaston is defined by potential pharmacodynamic interactions that stem from the herbal extract’s documented influence on specific hormonal and neurotransmitter pathways. This is the primary basis for all documented interaction statements.

Due to the possible dopaminergic effects of the Vitex agnus-castus fruit extract, potential interactions with co-administered Dopamine Agonists and Dopamine Antagonists cannot be excluded, a classification found in regulatory summaries. Furthermore, the possible oestrogenic effects of the extract require specific consideration for co-administration with products containing Oestrogens, such as hormonal contraceptives or hormone replacement therapy, and with Anti-Oestrogens. These combinations are officially categorized as use-with-caution but are not universally prohibited.

The product's profile includes a restriction related to its formulation. The oral liquid/drops version contains ethanol as an excipient, and this component must be taken into account when the medicine is co-administered with any other medicinal product known to interact with alcohol.

Official regulatory documents do not provide information or documentation for pharmacokinetic interactions concerning the CYP450 enzyme system or drug transporters. Consequently, the drug’s official interaction structure is not based on metabolic interference or the need for administration timing separation to manage plasma levels.

The mechanism of action for the Vitex Agnus Castus extract is driven by pharmacodynamic interactions that achieve neuroendocrine modulation. The process begins at the anterior pituitary gland, where active diterpenes in the extract act as agonists at the Dopamine D2 receptors . This direct molecular interaction initiates an inhibitory cascade that effectively suppresses the synthesis and secretion of prolactin (PRL).

The resulting altered prolactin levels reduce the inhibitory influence on the Hypothalamic-Pituitary-Ovarian (HPO) axis, allowing for changes in hormonal feedback loop activity. This cascade affects the function of the corpus luteum during the second half of the menstrual cycle, leading to altered synthesis of endogenous progesterone and modified hormonal signaling dynamics. The extract also contains components, such as certain flavonoids, that engage mu- and delta-opioid receptors in the CNS, resulting in auxiliary central signaling. The full physiological change requires time-dependent modulation of the HPO axis and consistent receptor engagement.

How to Use Agnucaston: Official Administration Guidelines

Administration of Agnucaston is strictly via the oral route, defining the fundamental method of delivery for the medicine. It is primarily available in two dosage preparations: the film-coated tablet and oral drops, which contain the standardized Vitex agnus-castus dry extract.

---

Standard Daily Regimen

The official dosage protocol requires once daily administration. For the tablet form, the standard regimen involves taking one film-coated tablet once daily. Depending on the specific product formulation, this corresponds to a daily dose of 4.0 mg or up to 20 mg of the dry extract. For the liquid form, the standard is typically 30–40 drops once daily. The medicine may be taken with or without food and should be consumed at a consistent time each day.

---

Use Duration and Procedural Instructions

Proper use of Agnucaston is structured around a continuous course duration. To achieve the intended use pattern, the medicine is taken for a minimum of three months, or the equivalent of three consecutive menstrual cycles, and treatment continues without interruption, including during menstruation. Procedurally, the film-coated tablets must be swallowed whole and unchewed with a sufficient amount of liquid. If a dose is missed, a double dose should not be taken; instead, the next dose should be resumed at the regular scheduled time. Furthermore, use is not recommended in children and adolescents under 18 years of age due to the absence of adequate safety and efficacy data.

Agnucaston: Recent Clinical Evidence

Evidence for Use in Premenstrual Syndrome (PMS)

Agnucaston (containing Vitex agnus-castus fruit extract) was the subject of research exploring symptoms associated with Premenstrual Syndrome (PMS), a condition characterized by fluctuating or episodic manifestations. The primary evidence comes from Randomized Controlled Trials (RCTs), reviewed in systematic meta-analyses, that monitored adult women with PMS over periods of two to three consecutive menstrual cycles. Researchers monitored outcomes related to physical discomfort, such as cyclical breast tenderness (mastalgia), and outcomes reflecting daily functioning, including mood alterations and irritability. Research also examined changes in certain biological markers during the study period.

Study Design, Comparison, and Results

The key research scenario compares the observed responses of women taking the extract against those receiving a placebo. Some studies also included groups taking other substances, such as Vitamin B6, which was evaluated in trials as an active comparator. Research describes patterns observed in the studies. However, results often varied across different studies due to high methodological heterogeneity (differences in trial design and extract preparation), contributing to variability in findings across the entire body of research.

Long-Term Data and Research Gaps

Most research was observed in studies designed for short-term to intermediate-term follow-up (approximately two to three months). As a result, long-term effects are not fully established, and evidence exploring the durability of observed symptom patterns remains insufficient.

Data for certain groups remain insufficient. For instance, comparative evidence is lacking regarding how the extract performs directly against current standard pharmacological therapies for PMS in well-designed, large-scale contemporary trials. Limited data exist for populations that fall outside the typical study demographics, such as children or older adults. Findings describe group patterns, not personal outcomes, and highlight what is known—and what is still uncertain.

Common questions about Agnucaston (FAQ)

---

Q: What are the main conditions Agnucaston is officially used for?

Regulatory documents state that Agnucaston is officially indicated for the treatment of Premenstrual Syndrome (PMS). It is also indicated for the treatment of cyclical breast pain and sensitivity, a condition known as mastodynia.

---

Q: How quickly can someone expect Agnucaston to start having an effect?

Official product information indicates that the product requires time for the therapeutic effect to develop. Improvement for menstrual disorders and related discomfort may require use for a continuous period of at least three months. The recommended usage period aligns with the duration of three consecutive menstrual cycles.

---

Q: Why do some people say Agnucaston helps with mood swings?

The product is indicated for the treatment of Premenstrual Syndrome (PMS). Official studies include monitoring symptoms like mood swings and irritability, as these are included among the recognized manifestations of PMS.

---

Q: Can Agnucaston be taken at the same time as hormonal birth control?

Official product information states that potential interactions with hormone-containing medications, such as oral contraceptives, cannot be ruled out. This is due to the potential hormonal influence of the active ingredient. For this reason, it is advised to consult a health care professional before considering concurrent use.

---

Q: Is it normal to feel tired or dizzy when first starting Agnucaston?

Side effects such as headache and dizziness have been reported in official documents, though their frequency is classified as rare or not known. Fatigue is also a reported effect. Patients experiencing these or any other side effects are encouraged to seek advice from a healthcare provider.

---

Q: Does Agnucaston affect the liver or kidneys?

Regulatory documents note that specific data regarding the dosage and use of Agnucaston in patients with existing impaired kidney or liver function are not available. Regulatory documents indicate that data for establishing safe use in this patient population are currently insufficient.

---

Q: Are there specific foods or drinks that interact with Agnucaston?

According to official administration guidelines, Agnucaston may be taken with or without food. The product information does not specify any known negative interactions with common foods or non-alcoholic beverages.

---

Q: Can someone take Agnucaston if they have a history of endometriosis?

Official documents advise that use should be avoided in women with a history of hormone-sensitive conditions. This includes conditions such as endometriosis or uterine fibroids.

---

Q: Why do regulatory bodies classify Agnucaston as a medicinal product in some regions?

In some regions, Agnucaston is formally classified as an authorized herbal medicinal product. This classification is based on its specific therapeutic indications for certain medical conditions, such as PMS and mastodynia, which are supported by pharmacological studies.

---

Q: Does Agnucaston help with all symptoms of PMS, or only specific ones?

The official indications state that Agnucaston is used for treating a range of specific PMS symptoms. These symptoms include physical discomfort like breast swelling and abdominal pain, as well as mood-related symptoms like restlessness and irritability.

---

Q: Does the manufacturing process of Agnucaston meet any specific quality standards?

The product is manufactured as a registered herbal medicine containing a standardized extract. As a manufacturer of phytomedicines, the company ensures the product adheres to quality standards, including ensuring the plants used in the manufacturing process are not genetically modified.

---

Q: Does Agnucaston cause weight gain or changes in appetite?

Weight gain or changes in appetite are not listed among the core documented adverse reactions. However, occasional fluctuations in body weight have been reported in association with the active ingredient in some cases.

---

Q: What are the known interactions between Agnucaston and antidepressant medications?

Official product information warns that potential interactions cannot be ruled out with medications that affect the central nervous system. This caution includes certain medicines used for mental health conditions, such as some antidepressants, due to the product’s dopaminergic effects.

---

Q: Is it safe to stop taking Agnucaston suddenly?

According to official documents, sudden discontinuation of the treatment is generally not associated with any special symptoms. Withdrawal phenomena are not typically reported when stopping the medicine.

---

Q: Does Agnucaston contain gluten, lactose, or other common allergens?

The film-coated tablets are certified as gluten-free. However, the tablets contain lactose. For patients with a specific intolerance to lactose, it is important to review this with a healthcare professional.

---

Q: Is Agnucaston known to affect fertility or conception?

Due to the product's potential for hormone-like actions, official sources note that use is not recommended for women who are actively trying to conceive. Furthermore, regulatory documents note that specific studies evaluating the effect on fertility have not been conducted.

---

Q: Is the active ingredient in Agnucaston considered a hormone?

The active ingredient itself is not classified as a hormone. Its therapeutic effects are primarily attributed to its indirect action on various neurotransmitters, which in turn influences the regulation of existing hormones within the body.

---

Q: Can Agnucaston be used by women approaching menopause?

The active ingredient in Agnucaston has been used in Herbal Medicine to help relieve symptoms associated with menopause. This includes symptoms such as hot flushes.

---

Q: Are there any contraindications related to mental health conditions?

Official warnings advise use with caution for patients who have a current or history of certain psychotic disorders. This is noted due to the product's documented potential for dopaminergic effects on the central nervous system.

---

Q: Are there any warnings about driving or operating machinery while taking Agnucaston?

Formal studies regarding the effect of Agnucaston on the ability to drive or use machinery have not been performed. However, due to reported side effects such as dizziness and confusion, patients should be aware of the potential for dizziness or confusion when performing these tasks.

---

Q: Are there any warnings about overdose associated with Agnucaston?

Regulatory documents state that overdose is considered extremely unlikely. Furthermore, there have been no known cases of overdose reported with this product.

---

Q: What is the expected timeline for consulting a doctor if symptoms don't improve?

Official documentation advises seeking consultation with a health care professional if symptoms worsen during use. Seeking advice is also recommended if no improvement is observed after a continued use of three months.

---

Q: Is Agnucaston suitable for people following a vegan or vegetarian diet?

The film-coated tablets contain lactose monohydrate. Since this excipient is derived from milk, individuals following a strict vegan diet should be aware of this content.

Agnucaston must be kept out of the sight and reach of children as a universal storage requirement.

Storage Requirements

Official labeling for Agnucaston film-coated tablets states that the product does not require any special storage conditions when kept in the original packaging, but the storage temperature must be maintained below 30 C in some regions.

The medicine must be stored in the original container to ensure protection from environmental factors and must not be used after the expiry date (EXP) printed on the carton.

• Handling: The liquid oral drops formulation is often subject to a post-opening stability rule, typically requiring use within a limited period after the bottle is first opened.

Disposal Instructions

Expired or unused Agnucaston must not be disposed of via household waste or wastewater. Regulatory documents require that you ask your pharmacist how to correctly dispose of the medicine or return it to the nearest pharmacy for proper pharmaceutical waste handling.